Alloy places the words bioidentical, FDA-approved and daily pill together on its progesterone page. They are easy to read as a single assurance, but each concerns a different property. Chemical identity, regulatory status and physical form need to be understood separately before that description becomes a record of an actual medicine.
This September 29, 2026 assessment examines the pill offer and its purchase conditions. It uses exact product-label and FDA information to explain what the terminology can establish, without assuming that Alloy supplies the reference product. No prescription, pharmacy order or ingredient verification was completed.
Read this article by section
Read the three claims as separate pieces of information
The Alloy listing establishes a prescription progesterone pill offered through menopause care. It describes the pill as bioidentical and FDA-approved, but does not name the manufacturer or provide a complete dispensing label. The approval statement is therefore a published provider claim, not independent confirmation of the selected product.
A useful comparison would retain all three properties instead of replacing them with a broader reassuring word such as natural. Midi’s assessment concerns a capsule explicitly described as compounded, demonstrating why two progesterone offerings can require different regulatory explanations even when their active hormone names resemble one another.
Chemical identity does not name a finished capsule
The official Prometrium label describes progesterone synthesized from a plant starting material as chemically identical to progesterone of ovarian origin. The same label separately identifies an oral micronized formulation. These statements concern a particular product record; they do not establish what Alloy would dispense.
Our micronized terminology guide examines why the additional word matters without treating it as a quality score. A statement about molecular identity cannot provide the inactive ingredients, manufacturer or route of an unnamed medicine. Those details would need to come from the actual prescription and product information, rather than from the most familiar approved brand containing that hormone.
Approval has requirements beyond using the same hormone name
FDA’s generic-drug explanation describes requirements involving the active ingredient, strength, dosage form, administration route and bioequivalence to the reference drug. A marketing page mentioning progesterone does not demonstrate those requirements for every possible preparation with that ingredient.
This does not cast doubt on an identified approved generic. It explains why the identification step is essential before applying the regulatory framework. The bioidentical-and-approval guide separates chemical descriptions from approval of a finished medicine. Alloy’s public claim would become more informative when accompanied by the exact product intended for the order, allowing its own official information to be read rather than borrowed from another label. The regulator’s requirements concern a defined comparison between products. They do not turn the entire category of progesterone preparations into one approved medicine or establish that a provider’s brief description contains every necessary product detail.
An ingredient question belongs to the selected product
The Prometrium reference lists peanut oil and gelatin among its capsule ingredients, with some other ingredients differing between its labeled strengths. Those details should not be assigned automatically to Alloy’s unidentified pill or to every progesterone medicine.
Conversely, the absence of an ingredient list from the Alloy page cannot establish that its eventual product avoids a particular ingredient. The clinician and dispensing pharmacist need the exact preparation when discussing an allergy or formulation concern. The useful comparison is between complete product records, not between one detailed label and an empty space that has been interpreted as a favorable ingredient claim.
A route description is not permission to use another route
Alloy’s pill description identifies the advertised form, but does not support an alternative route of administration. The oral, vaginal and topical discussion explains why those words cannot simply be exchanged while preserving the same evidence.
The Prometrium label, for example, identifies oral administration for that product. Its formulation and label do not authorize a reader to create a different use from a general progesterone discussion. Wisp’s review considers another terminology problem: different medicines appearing beneath a shared service heading. In both cases, accurate identity needs to precede any judgment about a proposed prescription.
The supply description leaves a price question unresolved
The product page pairs a starting $23 one-month display with text describing a three-month supply. The care page lists a separate one-time $49 consultation. This review does not resolve the differing product-period descriptions into a selected charge or assume a capsule quantity.
Alloy’s terms also distinguish notice at least seven days before subscription renewal from at least five business days before shipment processing. Clinical service fees are nonrefundable; a conditional refund for the first product shipment has a thirty-day window. A quote should identify the real product and purchase period alongside these conditions, rather than present the smallest visible amount as complete care.
The offer does not establish a product-specific outcome
Alloy’s page discusses symptom improvement among customers taking menopause hormone therapy. That broader treatment description is not a trial establishing the independent effect of an unidentified progesterone pill. The same page includes a qualification involving a uterus and certain progestin IUDs; this review does not assess any individual device or need for treatment.
The strongest supported conclusion is an actual prescribing offer with incomplete finished-product information. Before the terminology can answer a practical medicine question, the selected product, its own labeling, the treatment purpose and the full purchase need to be identified. Neither an approval adjective nor a customer-improvement statement supplies those missing details or predicts a reader’s response.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Alloy: progesterone pill offerProvider bioidentical/FDA-approved pill wording attributed; no supplied manufacturer or ingredient label confirmed, one-month price and three-month supply wording unresolved · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsule label, updated July 23, 2026Official structured label for the named oral product; chemical identity, micronization, formulation-specific ingredients and indications, not evidence of a reviewed provider supplying it · Checked 2026-09-29
- FDA: Generic Drug FactsFederal generic-drug approval explanation; exact active ingredient, strength, dosage form, route and bioequivalence requirements, not a selected product or substitution instruction · Checked 2026-09-29
- Alloy: hormone replacement therapyProvider clinical offer and one-time consultation fee; treatment categories not a personal recommendation · Checked 2026-09-29
- Alloy: terms of useDated platform terms; subscription and shipment cancellation deadlines, first-shipment refund conditions and service-fee exclusions kept separate · Checked 2026-09-28